# Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

> **NCT01762150** · PHASE2 · COMPLETED · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 26 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01762150
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2016-12
- **Final completion:** 2018-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762150, "Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01762150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*